Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) CongressGlobeNewsWire • 08/15/22
Amarin Corporation plc (AMRN) CEO Karim Mikhail on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/03/22
Amarin Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/03/22
Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022GlobeNewsWire • 07/20/22
NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & WalesGlobeNewsWire • 07/13/22
REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and PlaceboGlobeNewsWire • 06/30/22
Amarin Receives Positive Recommendation from United Kingdom's (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl)GlobeNewsWire • 06/10/22
Amarin Corporation plc's (AMRN) CEO Karim Mikhail on 2022 Jefferies Global Healthcare Conference (Transcript)Seeking Alpha • 06/08/22
Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. BusinessGlobeNewsWire • 06/06/22
Amarin Corporation Plc (AMRN) CEO Karim Mikhail on H.C. Wainwright Global Investment Conference (Transcript)Seeking Alpha • 05/25/22